Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 2

Microbiome and Association With Implant Infections: Investigating the Impact of Antibiotics on the Gut and Breast Microbiomes Post-mastectomy With Implant-based Breast Reconstruction

NCT ID: NCT05020574Sponsor: University of California, San FranciscoLast updated: 2026-03-18

Summary

The most common tissue expander-related infections are from Staphylococcus and Pseudomonas species. In addition, from breast tissue microbiome studies, Staphylococcus and Pseudomonas show variable abundance across samples. The investigator hypothesizes that participants undergoing mastectomy with high initial abundance of Staphylococcus and/or Pseudomonas are more likely to develop subsequent tissue expander-related infections from these respective organisms.

Detailed description

PRIMARY OBJECTIVE: I. To determine the feasibility of breast microbiome sampling using the study techniques SECONDARY OBJECTIVES: I. To define the differences in the gut and breast microbiomes between participants undergoing mastectomy with implant-based reconstruction who develop post-operative implant infection and those who do not. II. To determine the effects of post-operative antibiotics on the gut and breast microbiomes after mastectomy with implant-based reconstruction. OUTLINE: Participants are randomized to 1 of 2 cohorts. COHORT A: Participants receive postoperative antibiotics to take for at least 7 days post-operatively. COHORT B: Participants receive no antibiotics post-operatively in the absence of clinical evidence of infection. Participants are followed up for 90 days.

Arms & interventions

  • DrugCephalexin

    Given orally (PO)

Outcome measures

Primary

  • Proportion of tissue samples obtained successfully over time

    The feasibility of success in obtaining samples from breast tissue will be measured as a binary outcome (successful or not successful) over time (intra-operatively, week 1, week 2, week 3, and week 4). The investigators will assess and document success in obtaining a tissue sample immediately at the time of sampling of each participant.

    Time frame: 90 days

  • Proportion of aspirate samples obtained successfully overall

    The feasibility of success in obtaining samples from the tissue expander aspiration ports will be measured as a binary outcome (successful or not successful) over time (intra-operatively, week 1, week 2, week 3, and week 4). The investigators will assess and document success in obtaining a aspirate sample immediately at the time of sampling of each participant.

    Time frame: 90 days

  • Proportion of tissue samples successfully producing microbiome data

    Feasibility based off of the success rates in producing microbiome data from tissue samples in each patient will be measured as a binary outcome (successful or not successful) and will be reported.

    Time frame: 90 days

  • Proportion of aspirate samples successfully producing microbiome data

    Feasibility based off of the success rates in producing microbiome data from tissue samples in each patient will be measured as a binary outcome (successful or not successful) and will be reported.

    Time frame: 90 days

  • Proportion of any samples successfully producing microbiome data

    Feasibility based off of the success rates in producing microbiome data from tissue or aspirate samples in each patient will be measured as a binary outcome (successful or not successful) and will be reported.

    Time frame: 90 days

  • Correlation of the change in breast microbiome over time with total duration of antibiotics (Cohort A only)

    The investigators will analyze the microbiomes between groups, between microbiome environments (gut v. breast, inter-individual). The correlate of change in breast microbiome over time will be compared to the total duration of antibiotics for Cohort A only. The measure of association ranges from +1 to -1, with a value of zero equal to no association.

    Time frame: 90 days

Secondary

  • Proportion of participants with post-operative infection

    Time frame: 90 days

  • Shannon Diversity Index Score for species of microbiome

    Time frame: 90 days

  • Number of overall identified microbes

    Time frame: 90 days

Eligibility criteria

Sex: FemaleAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: 1. Patients must have histologically confirmed breast malignancy OR genetic predisposition to breast cancer. 2. Age \>= 18 years 3. Scheduled to undergo mastectomy with the immediate placement of tissue expanders or implant placement 4. Ability to understand a written informed consent document, and the willingness to sign it 5. At least 4 weeks post-completion of chemotherapy or radiation therapy. Exclusion Criteria: 1. Any significant medical condition or laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study 2. Pregnant or breastfeeding 3. Patients who have taken antibiotics within 90 days of the consent date 4. Patients who have taken probiotics within 90 days of the consent date 5. Patients who have a documented or reported allergic reaction to the outlined antibiotics to be used in this study 6. Male patients

Study locations (1)

University of California, San Francisco

San Francisco, California, 94143

Recruiting
Laura Barnes, MD · Contact
Merisa Piper, MD · Principal Investigator
Laura Barnes, MD · Sub Investigator
Michael Campbell, PhD · Sub Investigator